Retrovirus Epidemiology Donor Study (REDS): Special Repository Collections (SR) - Catalog

Name

Retrovirus Epidemiology Donor Study (REDS): Special Repository Collections (SR)

Accession Number

HLB01921010a

Acronym

REDS-SR

Related studies

BSI Study IDs

SPL

SRA

RED

Is public use dataset

False

Keywords

Has Study Datasets

False

Has Specimens

True

Specimen ID Type

Coded

Study Website

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

False

Study type

Epidemiology Study

Collection Type

Open BioLINCC Study

Cohort type

---------

Interventions

None

Study Open Date (Data)

None

Study Open Date (Specimens)

2010-05-05

Date materials available

2010-05-05

Last updated

None

Study period

1990 - 2002

Study Contacts
NHLBI Division

DBDR

Classification

Transfusion Medicine

HIV study classification

HIV

COVID study classification

---------

Pre-Website # of Specimens Shipped

46250

# of Returned Specimens

0

Primary Publication URLs
N/A
Conditions

Acquired Immunodeficiency Syndrome
Blood Donors
Blood Transfusion
HIV Infections
HIV-1
HIV-2
HTLV-I
HTLV-II
Retroviridae Infections

Objectives

The objective REDS-I was to develop a major multicenter epidemiologic study of the human retroviruses HIV-1, HIV-2, HTLV-I, and HTLV-II in volunteer U.S. blood donors. Blood samples collected at the time of donation and/or in follow-up visits, were submitted to special repositories. Criteria for submission to these special repository collections were the status of HTLV and HIV testing.

Background

REDS completed the collection of a large inventory of blood specimens from donors with specific test results for epidemiological and/or laboratory investigations of particular subpopulations of donors as the need arises. These eight special repositories (SRs) consist of specimens from donors who tested positive on routine screening assays, such as HTLV and HIV. Because of the unique linkage to demographic data and donation test results collected in the study database, investigations using these samples can be targeted to particular subsets of the blood donor population.


REDS blood centers that contributed to these repositories include:



  • American Red Cross - Greater Chesapeake and Potomac Region, Baltimore, MD;

  • American Red Cross - Southeastern Michigan Region, Detroit, MI;

  • American Red Cross - Southern California Region, Los Angeles, CA;

  • Blood Centers of the Pacific - San Francisco, CA; and

  • Oklahoma Blood Institute - Oklahoma City, OK.

Subjects

Design

Conclusions

Disease classification

Publications



  1. Kleinman S, Kaplan J, Khabbaz R, Calabro M, Thomson R, Busch M, and the REDS Study Group. Evaluation of a p21e-spiked Western blot (Immunblot) in confirming human T-cell lymphotropic virus type I or II infection in volunteer blood donors. J Clin Microbiol. 1994; 32: 603-607.




  2. Busch M, Laycock M, Kleinman S, Wages J Jr, Kaplan J, Khabbaz R, Hollingsworth C, and the REDS Study Group. Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Blood. 1994;83:1143-1148.




  3. Busch M, Kleinman S, Williams A, Smith J, Ownby H, Laycock M, Lee L, Pau C, Schreiber G. and the REDS Group. Frequency of human immunodeficiency virus (HIV) infection among contemporary anti-HIV-1 and anti-HIV-2 supplemental test-indeterminate blood donors. Transfusion. 1996;36:37-144.




  4. Kleinman S, Busch M, Ownby H, Williams A, Gilcher R. HIV p24 antigen (Ag) indeterminate (Ind) donors are not infected with HIV (abstract). Transfusion. 1997; 37S:98S.



Mat types

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

  • Material Types
  • General Freeze/Thaw Status
  • Visits (Vials)

    10/26/2018

      Serum Plasma Whole Blood Platelets PBMC Total
    1 Visit per Subject 3,005 75,213 61,616 1,289 16,088 157,211
    No Visit Date 0 6,626 0 0 0 6,626

     


    Last Modified: Oct. 26, 2018, 9:58 a.m.
  • Visits (Subjects)

    10/26/2018

      Serum
    Total number of subjects Average volume (ml) per subject
    1 Visit per Subject 1,418 3.12
     
      Plasma
    Total number of subjects Average volume (ml) per subject
    1 Visit per Subject 19,534 7.22
    No Visit Date 2,544 0.89
     
      Whole Blood
    Total number of subjects Average volume (ml) per subject
    1 Visit per Subject 15,560 4.26
     
      Platelets
    Total number of subjects Average vials per subject
    1 Visit per Subject 330 3.91
     
      PBMC
    Total number of subjects Average vials per subject
    1 Visit per Subject 2,930 5.49

     

    Last Modified: Oct. 26, 2018, 9:58 a.m.